| Xero Limited (XRO) ORDINARY FULLY PAID |
Information Technology |
$19,920 |
Change of Director's Interest Notice
|
19 Nov 2025 9:07AM |
$118.250 |
$120.390 |
risen by
1.81%
|
|
| Evion Group NL (EVG) ORDINARY FULLY PAID |
Materials |
$16 |
EU Raw Materials Week 2025 Presentation
|
19 Nov 2025 9:06AM |
$0.032 |
$0.030 |
fallen by
6.25%
|
|
| Boom Logistics Limited (BOL) ORDINARY FULLY PAID |
Industrials |
$64 |
Update - Notification of buy-back - BOL
|
19 Nov 2025 9:06AM |
$1.435 |
$1.585 |
risen by
10.45%
|
|
| ResMed Inc. (RMD) CDI 10:1 FOREIGN EXEMPT NYSE |
Health Care |
$22,740 |
4 Statement of changes in beneficial ownership of securities
|
19 Nov 2025 9:06AM |
$37.820 |
$39.310 |
risen by
3.94%
|
|
| Dimerix Limited (DXB) ORDINARY FULLY PAID |
Health Care |
$288 |
Successful Completion of Planned IDMC Review
|
19 Nov 2025 9:05AM |
$0.460 |
$0.480 |
risen by
4.35%
|
|
DXB - Price-sensitive ASX Announcement
Full Release
Key Points
- Dimerix Limited successfully completed the seventh IDMC review for the ACTION3 Phase 3 FSGS Kidney Trial.
- The IDMC recommended that the trial continue unchanged, without any changes to design or safety monitoring.
- No safety concerns were noted, reinforcing the strong safety profile of DMX-200.
- 271 patients have been enrolled in the ACTION3 Phase 3 clinical trial as of November 18, 2025.
- The next IDMC meeting is scheduled for the second quarter of 2026.
- DMX-200 is being tested as a treatment for FSGS, a serious kidney disorder, in a multi-centre, double-blind, placebo-controlled study.
- Dimerix is a clinical-stage biopharmaceutical company focused on developing treatments for inflammatory diseases, including kidney and respiratory diseases.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Tinybeans Group Ltd (TNY) ORDINARY FULLY PAID |
Communication Services |
$17 |
Trading Halt
|
19 Nov 2025 9:05AM |
$0.120 |
$0.103 |
fallen by
14.58%
|
|
TNY - Price-sensitive ASX Announcement
Full Release
Key Points
- Tinybeans Group Ltd (ASX: TNY) requested a trading halt.
- The halt is pending an announcement related to a proposed capital raising.
- The trading halt is in effect until the earlier of a market announcement or the start of trading on 21 November 2025.
- Tinybeans' request for the trading halt was approved by its Board.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Horizon Oil Limited (HZN) ORDINARY FULLY PAID |
Energy |
$321 |
AGM - Chairman & CEO's address and presentation
|
19 Nov 2025 9:05AM |
$0.195 |
$0.198 |
risen by
1.28%
|
|
HZN - Price-sensitive ASX Announcement
Full Release
Key Points
- Horizon Oil achieved five consecutive years of distribution yields of 15% or greater.
- Successful acquisition of Thailand upstream assets Nam Phong and Sinphuhorm from ExxonMobil.
- Focus on three key strategic pillars: free cash flow, low-cost operations, and strong production levels.
- Continued investment in production growth across core assets, including Mereenie and Block 22/12.
- Successful 10-year permit extension at Maari, ensuring long-term production stability.
- Enhanced ESG focus with better-than-industry safety metrics and reduced emissions.
- Strategic moves have positioned Horizon well for future growth and diversification in Southeast Asia.
- Anticipated stable production of over 6,500 boepd for at least the next three years.
- Continued shareholder distribution with a total of AUD 15.5 cents per share since 2021.
- Plans for further development and infill drilling at Maari and Block 22/12 in China.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Prospect Resources Limited (PSC) ORDINARY FULLY PAID |
Materials |
$127 |
Strong Exploration Targets Identified at Mumbezhi
|
19 Nov 2025 9:04AM |
$0.180 |
$0.180 |
fallen by
0%
|
|
PSC - Price-sensitive ASX Announcement
Full Release
Key Points
- 11 strong electromagnetic conductors identified in Mumbezhi.
- Chipimpa cluster is a key target, resembling Nyungu Central.
- Phase 2 drilling completed, totaling 18,200 meters.
- Gold assays underway on 1,200 historical samples from Nyungu Central.
- Updated Mineral Resource estimate for Mumbezhi expected in Q1 2026.
- Exploration techniques include termite hill sampling and IP surveys.
- New targets identified at Kamafamba and Kamafamba West.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Ora Banda Mining Ltd (OBM) ORDINARY FULLY PAID |
Materials |
$2,437 |
AGM Presentation
|
19 Nov 2025 9:04AM |
$1.150 |
$1.280 |
risen by
11.30%
|
|
| Pengana International Equities Limited (PIA) ORDINARY FULLY PAID |
Financials |
$329 |
NTA at 14.11.25 Pre-tax 142.9 Post-tax 137.97
|
19 Nov 2025 9:04AM |
$1.275 |
$1.280 |
risen by
0.39%
|
|
| Clover Corporation Limited (CLV) ORDINARY FULLY PAID |
Materials |
$140 |
Notification regarding unquoted securities - CLV
|
19 Nov 2025 9:03AM |
$0.695 |
$0.840 |
risen by
20.86%
|
|
| Evion Group NL (EVG) ORDINARY FULLY PAID |
Materials |
$16 |
Change of Directors Interest Notice x 3
|
19 Nov 2025 9:03AM |
$0.032 |
$0.030 |
fallen by
6.25%
|
|
| HMC Capital Limited (HMC) ORDINARY FULLY PAID |
Financials |
$1,329 |
AGM 2025 Chair and CEO Address
|
19 Nov 2025 9:02AM |
$2.950 |
$3.220 |
risen by
9.15%
|
|
| Prescient Therapeutics Limited (PTX) ORDINARY FULLY PAID |
Health Care |
$72 |
PTX secures EU Orphan Drug Designation for PTX-100 in CTCL
|
19 Nov 2025 9:02AM |
$0.048 |
$0.068 |
risen by
41.67%
|
|
PTX - Price-sensitive ASX Announcement
Full Release
Key Points
- Prescient secures EMA Orphan Drug Designation for PTX-100 in CTCL.
- EMA designation provides major benefits including 10 years of EU market exclusivity.
- PTX-100 is in Phase 2a trials for relapsed/refractory CTCL.
- Complements existing U.S. FDA Orphan Drug and Fast Track status.
- CEO James McDonnell to hold an investor briefing on 25th November.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Red Mountain Mining Limited (RMX) ORDINARY FULLY PAID |
Materials |
$27 |
Red Mountain Up 36% with Successful Debut on Us Stock Market
|
19 Nov 2025 9:02AM |
$0.036 |
$0.031 |
fallen by
13.89%
|
|
RMX - Price-sensitive ASX Announcement
Full Release
Key Points
- Red Mountain Mining Limited (ASX: RMX) successfully debuted on the US stock market (OTCQB) with a 36% gain on its first trading day.
- The company's stock, trading under the US code RMXFF, reached a high of A$0.054 (US$0.035).
- Strong market activity and high levels of US-based investor engagement were noted during the debut.
- Red Mountain presented at the Australian Rare Earths & Critical Minerals Investor Conference.
- The company is engaged in discussions with strategic partners to fast-track its US and Australian critical minerals portfolio.
- Red Mountain's US portfolio includes Antimony Projects in Idaho and Utah, while the Australian portfolio includes Armidale Antimony-Gold Project.
- The company is leveraging US government funding programs and critical minerals project support.
- Red Mountain expects further results from its Armidale project by the end of November.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Orica Limited (ORI) ORDINARY FULLY PAID |
Materials |
$11,077 |
Change of Director's Interest Notice
|
19 Nov 2025 9:01AM |
$23.760 |
$23.690 |
fallen by
0.29%
|
|
| Xero Limited (XRO) ORDINARY FULLY PAID |
Information Technology |
$19,920 |
Change of Director's Interest Notice
|
19 Nov 2025 9:00AM |
$118.250 |
$120.390 |
risen by
1.81%
|
|
| Epsilon Healthcare Limited (EPN) ORDINARY FULLY PAID |
Health Care |
$9 |
Appendix 4G & Corporate Governance Statement
|
19 Nov 2025 9:00AM |
$0.024 |
$0.024 |
fallen by
0%
|
|
| Vulcan Energy Resources Limited (VUL) ORDINARY FULLY PAID |
Materials |
$1,423 |
Positive start to Phase One Lionheart field development
|
19 Nov 2025 8:58AM |
$6.710 |
$6.070 |
fallen by
9.54%
|
|
VUL - Price-sensitive ASX Announcement
Full Release
Key Points
- Strong drilling performance and subsurface results from LSC-1 and LSC-1a.
- Phase One Lionheart Project aims for 24,000 tonnes LHM production yearly.
- Project supports 500,000 battery electric vehicles annually.
- Vercana's efficient and on-schedule drilling boosts project confidence.
- Lithium grades and subsurface conditions consistent with existing standards.
- Next steps involve further sidetrack drilling and production tests.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Region Group (RGN) FULLY PAID UNITS STAPLED SECURITIES |
Real Estate |
$2,787 |
Update - Notification of buy-back - RGN
|
19 Nov 2025 8:58AM |
$2.380 |
$2.400 |
risen by
0.84%
|
|
| Ironbark Capital Limited (IBC) ORDINARY FULLY PAID |
Financials |
$45 |
Update - Notification of buy-back - IBC
|
19 Nov 2025 8:57AM |
$0.435 |
$0.430 |
fallen by
1.15%
|
|
| Pengana Private Equity Trust (PE1) ORDINARY UNITS FULLY PAID |
Financials |
$349 |
Update - Notification of buy-back - PE1
|
19 Nov 2025 8:57AM |
$1.310 |
$1.295 |
fallen by
1.15%
|
|
| Brambles Limited (BXB) ORDINARY FULLY PAID |
Industrials |
$32,553 |
Notification of cessation of securities - BXB
|
19 Nov 2025 8:57AM |
$23.300 |
$23.910 |
risen by
2.62%
|
|
| King River Resources Limited (KRR) ORDINARY FULLY PAID |
Materials |
$22 |
2025 RC Drill Program Kuiper - Tennant Creek
|
19 Nov 2025 8:57AM |
$0.016 |
$0.015 |
fallen by
6.25%
|
|
| Middle Island Resources Limited (MDI) ORDINARY FULLY PAID |
Materials |
$30 |
Significant Zinc & Lead Soil Anomalies defined in Tisovik
|
19 Nov 2025 8:56AM |
$0.029 |
$0.030 |
risen by
3.45%
|
|
MDI - Price-sensitive ASX Announcement
Full Release
Key Points
- Significant zinc and lead soil anomalies defined in Tisovik target at Bobija Project.
- Peak assay results of 2,733 ppm Pb and 899 ppm Zn reported.
- Anomalism extends up to 1.5 km long and 400 m wide.
- Exploration part of the Serbian exploration portfolio acquired via Konstantin Resources Ltd.
- Further soil sampling proposed to extend the survey area.
- Results for maiden RC drilling program expected shortly.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.